Non-ASH Meetings

Non-ASH Meetings

On-site interview with presenters at meetings and summits in the hematology/oncology arena

video

Does Blinatumomab Affect CAR T-Cell Therapy Response?

In new data from ZUMA-3, patients with acute lymphocytic leukemia responded to CD19-targeting CAR T-cell therapy, regardless of prior CD19-targeting therapy with blinatumomab. Bijal...
video

Venetoclax Plus Carfilzomib: A New Wave of Myeloma Treatment

Luciano Costa, MD, talks about the combination of venetoclax and carfilzomib, which led to an 83% response rate in patients with relapsed and heavily-refractory...
video

With bb2121, Is CAR T-Cell Therapy Ready for Myeloma?

Noopur Raje, MD, discusses updated data from a phase I trial of the second-generation, anti-BCMA CAR T-cell therapy for relapsed/refractory myeloma.
video

“Best Survival Data Yet” With Nelarabine in T-Cell ALL

Kimberly P. Dunsmore, MD, discusses results from the largest trial conducted of young patients with newly diagnosed T-cell acute lymphocytic leukemia, which produced survival...
video

Positive Results With Ivosidenib in IDH1-Mutated AML

Treatment with the highly selective IDH1 inhibitor ivosidenib led to a complete remission rate of 40%, with an overall survival of nearly 19 months...
video

Allogeneic Transplant Plus NK Cells in High-Risk Myeloma

Dr. Shah discusses natural killer cells for myeloma - a cellular therapy that "kills" without causing graft-versus-host disease.
video

Evaluating New Myeloma Agent Combinations in Lenalidomide-Refractory Patients

Dr. Chari reports results from a trial of daratumumab plus carfilzomib-dexamethasone in patients with lenalidomide-refractory disease.
video

Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML

Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an "impressive" response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr....
video

Jae Hong Park, MD: Improving Outcomes, Minimizing Toxicity With CAR T-Cell Therapy in B-Cell...

Dr. Park reviews two studies identifying characteristics that can improve durability of outcome, without increasing toxicity, in patients with B-cell acute lymphocytic leukemia.
video

Frederick Locke, MD: CAR T-Cell Therapy in Relapsed/Refractory NHL

Based on results of the ZUMA-1 trial, axicabtagene ciloleucel was submitted to the FDA earlier this year for patients with chemotherapy-refractory, aggressive non-Hodgkin lymphomas....
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.